Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.

Eric A JonesBenjamin P LinasVe TruongJames F BurgessKaren E Lasser

Published in: PloS one (2019)

The 340B Drug Pricing Program enabled a safety-net hospital to deliver effective primary care-based HCV treatment using a multidisciplinary care team. Efforts to sustain the 340B program could enable dissemination of similar HCV treatment models elsewhere.

Keyphrases

quality improvement
primary care
healthcare
palliative care
emergency department
human immunodeficiency virus
adverse drug